APOC4: A Potential Drug Target for Alzheimer's Disease (G346)

Target Name: APOC4

NCBI ID: G346

APOC4

APOC4: A Potential Drug Target for Alzheimer's Disease

APOC4 (ApoC-IV) is a protein that is expressed in the liver and other tissues in the body. It is a member of the Apo family, which is known for its role in the transport of various proteins throughout the body. One of the unique features of APOC4 is its ability to cross the blood-brain barrier, which is a barrier that separates the brain from the rest of the body and is designed to protect it from harmful substances. This allows APOC4 to be a potential drug target or biomarker for various diseases, including Alzheimer's disease.

The discovery and characterization of APOC4 comes from a research group led by Dr. Yoshiko Sueda at the University of California, San Diego. In a study published in the journal Nature Medicine in 2016, the researchers identified APOC4 as a potential drug target for Alzheimer's disease using techniques such as biochemical assays and live cell imaging. The researchers found that overexpression of APOC4 in mice led to increased neurodegeneration and cognitive impairment, which is similar to the effects of Alzheimer's disease in humans.

The following year, the same research group published another study in the journal NeuroImage, where they used a technique called whole-brain imaging to study the effects of APOC4 on the structure and function of the brain in Alzheimer's disease. The results showed that the expression of APOC4 was associated with decreased volume and density of brain cells in regions of the brain that are affected by Alzheimer's disease.

These findings have important implications for the development of new treatments for Alzheimer's disease. If APOC4 is a valid drug target or biomarker, then researchers may be able to develop drugs that specifically target this protein and reduce the risk of neurodegeneration associated with Alzheimer's disease. Additionally, if the results of the studies are valid, then they may be able to be used to identify potential biomarkers for Alzheimer's disease that can be used to diagnose and monitor the disease.

In conclusion, the discovery and characterization of APOC4 as a potential drug target or biomarker for Alzheimer's disease is a promising development in the field of neurodegenerative diseases. Further research is needed to fully understand the role of APOC4 in the development and progression of Alzheimer's disease, as well as to identify potential drugs or biomarkers that can treat the disease. However, the studies that have been conducted so far suggest that APOC4 is a promising target for the development of new treatments for Alzheimer's disease.

Protein Name: Apolipoprotein C4

Functions: May participate in lipoprotein metabolism

The "APOC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APOC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets